Literature DB >> 30175608

[The role of gut microbiota in chronic liver diseases, and treatment possibilities].

Krisztina Hagymási1, Anna Bacsárdi2, Anna Egresi1, Evelin Berta2, Zsolt Tulassay1, Gabriella Lengyel1.   

Abstract

The community of microorganisms in the intestine, namely gut microbiome lives in symbiosis with the host, contributing to its homeostasis and influencing it simultaneously. It can be suspected that gut microbiome plays a central role in the pathophysiology of intestinal and extraintestinal diseases: determining their development, progress and complications. Recently, intestinal microbiome has become a highlighted field of interest and important topic in research, especially in hepatology. It is in the focus of relevant research as the liver is the organ which meets nutrients, bacterial components, toxins and metabolites at first, as a filter. The evolvement of different liver diseases - just like alcoholic and non-alcoholic fatty liver disease, steatohepatitis, cirrhosis or hepatocellular carcinoma - correlates with the changed composition and activity of gut microbiome. Thus, it can be hypothesized that pre-, pro- and antibiotics could have an impact on the treatment of these diseases. In our review article, the relationship between intestinal flora and liver diseases with different etiologies as well as therapeutic possibilities are discussed. Orv Hetil. 2018; 159(36): 1465-1474.

Entities:  

Keywords:  bélpermeabilitás; dysbiosis; gut permeability; liver diseases; microbiome; microbiota; mikrobiom; mikrobióta; májbetegségek; prebiotics; prebiotikumok; probiotics; probiotikumok; rebiosis

Mesh:

Year:  2018        PMID: 30175608     DOI: 10.1556/650.2018.31178

Source DB:  PubMed          Journal:  Orv Hetil        ISSN: 0030-6002            Impact factor:   0.540


  3 in total

1.  Beneficial effects of LRP6-CRISPR on prevention of alcohol-related liver injury surpassed fecal microbiota transplant in a rat model.

Authors:  Linghua Yu; Linlin Wang; Huixing Yi; Xiaojun Wu
Journal:  Gut Microbes       Date:  2020-03-13

2.  Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial.

Authors:  Lanfeng Xue; Zhiliang Deng; Wenhui Luo; Xingxiang He; Yu Chen
Journal:  Front Cell Infect Microbiol       Date:  2022-07-04       Impact factor: 6.073

3.  Diosmetin has therapeutic efficacy in colitis regulating gut microbiota, inflammation, and oxidative stress via the circ-Sirt1/Sirt1 axis.

Authors:  Hai-Long Li; Yi-Ying Wei; Xiao-He Li; Shan-Shan Zhang; Ruo-Tong Zhang; Jin-He Li; Bo-Wei Ma; Shuai-Bo Shao; Zi-Wei Lv; Hao Ruan; Hong-Gang Zhou; Cheng Yang
Journal:  Acta Pharmacol Sin       Date:  2021-07-14       Impact factor: 6.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.